Tarsus Pharmaceuticals Inc Forecast, price target & analysts
Tarsus Pharmaceuticals Inc Target price 2026 - Analyst rating & recommendation
Tarsus Pharmaceuticals Inc Classifications & Recommendation
Tarsus Pharmaceuticals Inc Price Target
| Target Price | $90.78 |
| Price | $75.96 |
| Potential |
19.51%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Tarsus Pharmaceuticals Inc 2027 .
The average Tarsus Pharmaceuticals Inc target price is $90.78.
This is
19.51%
register free of charge
$109.20
43.76%
register free of charge
$84.84
11.69%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend Tarsus Pharmaceuticals Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Tarsus Pharmaceuticals Inc stock has an average upside potential 2027 of
19.51%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 451.36 | 730.33 |
| 146.71% | 61.81% | |
| EBITDA Margin | -15.32% | -12.29% |
| 76.51% | 19.78% | |
| Net Margin | -14.72% | -11.32% |
| 76.70% | 23.07% |
10 Analysts have issued a sales forecast Tarsus Pharmaceuticals Inc 2026 . The average Tarsus Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Tarsus Pharmaceuticals Inc EBITDA forecast 2026. The average Tarsus Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Tarsus Pharmaceuticals Inc Analysts have issued a net profit forecast 2026. The average Tarsus Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.59 | -1.91 |
| 48.21% | 20.13% | |
| P/E | negative | |
| EV/Sales | 4.35 |
10 Analysts have issued a Tarsus Pharmaceuticals Inc forecast for earnings per share. The average Tarsus Pharmaceuticals Inc EPS is
This results in the following potential growth metrics and future valuations:
Tarsus Pharmaceuticals Inc...
Current Tarsus Pharmaceuticals Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Sep 16 2026 |
| Jefferies |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Mizuho |
Locked
➜
Locked
|
Locked | Jul 31 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jul 21 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 09 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 04 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 16 2026 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Jul 31 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jul 21 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 09 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 04 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
